Asthma treatment

191. (MA) – June 26, 2001 $2. 75M TOWARD ASTHMA RESEARCH Pharmaceutical giant AstraZeneca has given Harvard Medical School and Brigham and Women’s Hospital $2. 75 million to establish a professorship and fund asthma research – the largest corporate gift ever made to the Brigham. The money creates an endowed chair at the school, the AstraZeneca Professorship in Respiratory and Inflammatory Diseases, which was awarded yesterday to Dr. K. Frank Austen. Interest income from the award will pay for basic and clinical immunobiology research …. 2. Independent, The (London, England)/Financial Times – August 7, 1998 The Independent: Zeneca suffers a pounds 112m triple blow A “TRIPLE WHAMMY” of sterling strength, the Asian crisis and the year 2000 computer bug wiped pounds 112m off Zeneca’s first-half profits, the pharmaceutical group revealed yesterday. The factors were behind a 2 per cent slide in interim pre-tax profits to pounds 654m despite a 5 per cent rise in sales to pounds 2. 90bn, the drugs group said. The interim dividend rose to 14p per share from 13. 5p a year ago. A worse-than-expected hit from sterling …. 3. Newstex Blogs (USA) – July 4, 2009 Popular Asthma Medicine Singulair Associated With Psychiatric Disorders In Children Jul. 4, 2009 ( Drug Injury Watch delivered by Newstex) New Medical Journal Article Follows June 2009 FDA-Required Warning For Singulair About Neuropsychiatric Events (Posted by Tom Lamb at DrugInjuryWatch. com) On June 12, 2009 the FDA announced a new warning about an increased risk of neuropsychiatric events for the asthma medicine Singulair (montelukast)– as well as some other less popular leukotriene inhibitors, Accolate (zafirlukast) as well as Zyflo and …. 4. Winchester (VA) – January 14, 2009 FDA: asthma drugs, suicide not linked WASHINGTON – Federal health officials said Tuesday that asthma drugs, including Merck’s Singulair, do not appear tied to suicide – though regulators continue to examine possible links to behavioral problems. After nine months of review, the Food and Drug Administration said company data do not show any association between the popular respiratory medications and suicide. However, the agency said the studies it reviewed were not designed to detect those events. “We …. 5. (WV) – January 14, 2009 FDA finds no link with asthma drugs, suicide WASHINGTON – Federal health officials said Tuesday that asthma drugs, including Merck’s Singulair, do not appear tied to suicide – though regulators continue to examine possible links to behavioral problems. After nine months of review, the Food and Drug Administration said company data do not show any association between the popular respiratory medications and suicide. However, the agency said the studies it reviewed were not designed to detect those events. “We …. 6. – January 13, 2009 FDA probe finds no link with asthma drugs, suicide Federal health officials said Tuesday that asthma drugs, including Merck’s Singulair, do not appear tied to suicide — though regulators continue to examine possible links to behavioral problems. After nine months of review, the Food and Drug Administration said company data do not show any association between the popular respiratory medications and suicide. However, the agency said the studies it reviewed were not designed to detect those events. “We have …. 7. – January 13, 2009 FDA probe finds no link with asthma drugs, suicide Federal health officials said Tuesday that asthma drugs, including Merck’s Singulair, do not appear tied to suicide — though regulators continue to examine possible links to behavioral problems. After nine months of review, the Food and Drug Administration said company data do not show any association between the popular respiratory medications and suicide. However, the agency said the studies it reviewed were not designed to detect those events. “We have …. 8. Herald and the Sunday Herald, The (Glasgow, Scotland) – August 7, 1998 The Herald (United Kingdom): Business: Zeneca braced for big hit: Currency problems loom large on balance sheet as pharmaceuticals firm boosts crucial US sales by 24% ZENECA yesterday claimed strong underlying progress in the first half of the year but its reported figures were marred by a heavy impact from the strong pound. This took Pounds 81m off profits, which were 2% down at Pounds 654m. The shares rose 12. 5p to 2281. 25p, compared with a speculation-driven peak of 2850p. Zeneca is seen as vulnerable to industry consolidation, although there has been no hint of any action. The interim dividend increased 4% to 14p. Chief executive Sir David …. 9. Spokesman-Review, The (Spokane, WA) – September 22, 2002 Hospitals scanning for drug mix-ups, Bar-code technology being adopted to avoid medication errors With pills named Glyburide and Glipizide sitting side by side on the shelf, it’s understandable that an overworked pharmacist might pull the wrong drug when filling an order. Similar in name and packaging, both drugs treat diabetes. The consequences of mixing them up would be small. But what if a patient got the anxiety drug Xanax instead the ulcer drug Zantac? Or the asthma drug Accolate instead of the hypertension drug Accupril? The error could lead to death. Some ….. Hamilton Spectator, The (Ontario, Canada) – October 21, 1999 ASTHMA TREATMENT LAGGING RESEARCH PAINFULLY SLOW DESPITE BONANZA AWAITING DRUG FIRMS New treatments have been noticeably slow in coming despite the seemingly endless rise in asthma cases. In the past two years, for example, three new drugs have been released to treat migraines, with another due in the spring. But for asthma, which accounts for more pediatric hospitalizations each year than any other illness, only two significant drugs were approved in the U. S. in the same period, Accolate by Astra-Zeneca and Singulair from Merck. These drugs, taken as pills, address the ….